Net price growth of 0.3% for branded drugs in 2018 was 1.6% below Consumer Price Index inflation, while invoice prices grew an average of 5.5%.
US brand drug prices grew at historically low amounts in 2018 at both the invoice price (before rebates and discounts) and net price (after rebates and discounts), according to a new drug spending report released on 9 May by the IQVIA Institute for Human Data Science.
Net price growth of 0.3% was 1.6% below Consumer Price Index inflation, while invoice price increases for branded drugs grew...
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
